The outlook of companies tied to Sildenafil's legacy presents a intricate investment picture . While the initial success generated substantial returns , generic alternatives have significantly eroded sales . Investing in related pharmaceutical businesses now requires a careful assessment of intellectual property rights , evolving patient changes, a